Lipid-coated hollow mesoporous silica nanospheres for co-delivery of doxorubicin and paclitaxel: Preparation, sustained release, cellular uptake and pharmacokinetics

Qiu, Yang; Wu, Chao; Jiang, Jie; Hao, Yanna; Zhao, Ying; Xu, Jie; Yu, Tong; Ji, Peng

doi:10.1016/j.msec.2016.10.081

Cited by 31 publications

(20 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A soap-free emulsion polymerization method was used to synthesize the monodispersed polystyrene nanospheres (PS) [ 20 ]. Briefly, styrene (40 g) was dripped slowly in distilled water (390 ml) containing 1 g DAC (80 wt%).…”

Section: Methodsmentioning

confidence: 99%

Biodegradable Alginate-Chitosan Hollow Nanospheres for Codelivery of Doxorubicin and Paclitaxel for the Effect of Human Lung Cancer A549 Cells

Liu

Jiang

Gao

et al. 2018

BioMed Research International

Self Cite

View full text Add to dashboard Cite

A biodegradable alginate coated chitosan hollow nanosphere (ACHN) was prepared by a hard template method and used for codelivery of doxorubicin (DOX) and paclitaxel (PTX) to investigate the effect on human lung cancer A549 cells. PTX was loaded into the nanometer hollow structure of ACHN through adsorption method. DOX was coated on surface of ACHN through electrostatic interaction. Drug release studies exhibited a sustained-release effect. According to X-ray diffraction patterns (XRD), differential scanning calorimetry (DSC), and Fourier transform infrared spectroscopy (FT-IR) analysis, DOX structure in the loading samples (DOX-PTX-ACHN) was of amorphous state while PTX was microcrystalline. Cytotoxicity experiments showed ACHN was nontoxic as carrier material and the combination of DOX and PTX in DOX-PTX-ACHN exhibited a good inhibiting effect on cell proliferation. Cell uptake experiments demonstrated that DOX-PTX-ACHN accumulated in the cytoplasm. Degradation experiments illustrated that ACHN was a biodegradable material. In summary, these results clearly indicate that ACHN can be utilized as a potential biomaterial to transport multiple drugs to be used in combination therapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Biodegradable Alginate-Chitosan Hollow Nanospheres for Codelivery of Doxorubicin and Paclitaxel for the Effect of Human Lung Cancer A549 Cells

Liu

Jiang

Gao

et al. 2018

BioMed Research International

Self Cite

View full text Add to dashboard Cite

show abstract

“…A previous report showed that HMSN was an ideal low-toxicity carrier even when the concentration achieved was as high as 400 µg/mL, which was more than ten times the therapeutic concentration used in our study. 49 Here, we evaluated the cellular toxicity of HMSNs and Tf-HMSNs in res-TPC-1 cells and res-BCPAP cells treated with interval concentrations of HMSNs for 48 hours. As evidenced in Figure S4, the cell viability was 98% at a maximum particle concentration of 400 µg/mL after 24-and 48-hour treatment, which confirmed the good safety and biocompatibility of this carrier system.…”

Section: The Cytotoxicity Assaymentioning

confidence: 99%

Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy

You¹,

Cheng²

2018

IJN

View full text Add to dashboard Cite

BackgroundThyroid cancer becomes the most common endocrine cancer with the greatest growing incidence in this decade. Sorafenib is a multikinase inhibitor for the treatment of progressive radioactive iodine-refractory differentiated thyroid cancer (DTC), while the off-target toxicity effect is usually inconvenient for patients taking.MethodsIn this study, hollow mesoporous silica nanoparticles (HMSNs) with transferrin modification (Tf-HMSNs) were loaded with sorafenib (sora@Tf-HMSNs) to help targeted delivery of sorafenib. Due to the biocompatible Tf shell, Tf-HMSNs exhibited excellent bio-compatibility and increased intracellular accumulation, which improved the targeting capability to cancer cells in vitro and in vivo.ResultsSora@Tf-HMSNs treatment exhibited the strongest inhibition effect of res-TPC-1 cells and res-BCPAP cells compared with sora@HMSNs and sorafenib groups and induced more cancer cell apoptosis. Finally, Western blot analysis was conducted to check the expression of RAF/MEK/ERK signaling pathway after sorafenib encapsulated Tf-HMSNs treatment.ConclusionOverall, sora@Tf-HMSNs can significantly increase the effective drug concentration in cancer cells and thus enhance the anticancer effect, which are expected to be promising nanocarriers to deliver anticancer drugs for effective and safe therapy for RAI-refractory DTC.

show abstract

“…PTX induces cell apoptosis by interfering with the normal functions of microtubules during cell mitosis (Wu et al., 2017 ; Zhao et al., 2017 ; Feng et al., 2019 ; Yang et al., 2019 ). The synergistic effects of DOX and PTX have been investigated in the treatment of breast cancer, lung cancer, melanoma, and hepatic carcinoma, however, their synergistic therapeutic efficacy against osteosarcoma has been poorly understood (Jin et al., 2010 ; Wang et al., 2011 , 2016 ; Zhao et al., 2011 , 2017 ; Liu et al., 2014 ; Baabur-Cohen et al., 2017 ; Qiu et al., 2017 ; Jiang et al., 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy

Hou

Zhang

et al. 2020

Drug Delivery

View full text Add to dashboard Cite

Nanoparticle-based drug delivery system offers a promising platform for combination cancer therapy. However, the inefficient drug release in cells reduces the therapeutic efficacy of cancer nanomedicines. Herein, a PEGylated poly(a-lipoic acid) copolymer (mPEG-PaLA) was prepared and used as a reduction/ pH dual responsive nanocarrier to simultaneously deliver paclitaxel (PTX) and doxorubicin (DOX) for osteosarcoma therapy. The amphiphilic mPEG-PaLA could efficiently encapsulate both PTX and DOX during its self-assembly into micelles in aqueous solution to generate PTX and DOX co-loaded nanoparticles (NP-PTX-DOX). The as-prepared NP-PTX-DOX showed enhanced PTX and DOX release in response to reductive and acidic stimuli. Moreover, the dual-drug loaded nanoparticles were efficiently internalized by K7 osteosarcoma cells and released drugs intracellularly, as confirmed by flow cytometry analysis and confocal laser scanning microscopy. Consequently, NP-PTX-DOX exhibited synergistic therapeutic effects and induced enhanced cell apoptosis in K7 cells. Furthermore, NP-PTX-DOX presented improved biodistribution and higher tumor growth inhibition efficacy compared to the control groups in a murine osteosarcoma model. Altogether, the results of this work indicate that the proposed strategy is promising for osteosarcoma therapy using mPEG-PaLA copolymer as a dual-responsive nanocarrier to co-deliver anticancer drugs.

show abstract

Lipid-coated hollow mesoporous silica nanospheres for co-delivery of doxorubicin and paclitaxel: Preparation, sustained release, cellular uptake and pharmacokinetics

Cited by 31 publications

References 35 publications

Biodegradable Alginate-Chitosan Hollow Nanospheres for Codelivery of Doxorubicin and Paclitaxel for the Effect of Human Lung Cancer A549 Cells

Biodegradable Alginate-Chitosan Hollow Nanospheres for Codelivery of Doxorubicin and Paclitaxel for the Effect of Human Lung Cancer A549 Cells

Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy

Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy

Contact Info

Product

Resources

About